{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:02:43Z","timestamp":1776801763886,"version":"3.51.2"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Public Health"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.puhe.2024.03.027","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T09:01:46Z","timestamp":1715850106000},"page":"86-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Lung cancer in Argentina: a modelling study of disease and economic burden"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4260-8239","authenticated-orcid":false,"given":"A.","family":"Alcaraz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3029-4439","authenticated-orcid":false,"given":"F.","family":"Rodriguez-Cairoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-7531","authenticated-orcid":false,"given":"C.","family":"Colaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-0991","authenticated-orcid":false,"given":"C.","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4966-4190","authenticated-orcid":false,"given":"C.","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-3561","authenticated-orcid":false,"given":"N.","family":"Espinola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.puhe.2024.03.027_bib1","unstructured":"Cancer. World Health Organization. Published February 3, 2022. Accessed May 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"issue":"9","key":"10.1016\/j.puhe.2024.03.027_bib2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S2213-2600(21)00164-8","article-title":"Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"Ebrahimi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.puhe.2024.03.027_bib3","article-title":"An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean","volume":"13","author":"Pi\u00f1eros","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.puhe.2024.03.027_bib4","series-title":"Cancer mortality bulletin in Argentina","author":"Ar\u00e1oz","year":"2020"},{"key":"10.1016\/j.puhe.2024.03.027_bib5","unstructured":"Jose Enrique Carrizo Olalla, Gisel Fattore, Cecilia Maturo. The institutional Registry of tumors in Argentina 2012-2020. Published May 27, 2021. Accessed July 26, 2023. https:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-02\/2023-02-Bolet%C3%ADn-RITA-v-f.pdf."},{"key":"10.1016\/j.puhe.2024.03.027_bib6","first-page":"1","article-title":"Health, economic and social burden of tobacco in Latin America and the expected gains of fully implementing taxes, plain packaging, advertising bans and smoke-free environments control measures: a modelling study","author":"Pichon-Riviere","year":"2023","journal-title":"Tob Control"},{"issue":"10299","key":"10.1016\/j.puhe.2024.03.027_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"issue":"suppl_4","key":"10.1016\/j.puhe.2024.03.027_bib8","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.puhe.2024.03.027_bib9","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.puhe.2024.03.027_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.puhe.2024.03.027_bib11","unstructured":"de Rito Mart\u00edn Lombardo Mart\u00edn Pont Verg\u00e9s Lionel Gaggino Romina Al\u00ed Josefina Ordenavia Santiago Torroba Julieta Arilla Joaqu\u00edn Lanuza Anal\u00eda Imperioso MCZHBF. Cobertura de Salud en Argentina. Ministerio de Salud de la Naci\u00f3n - Secretar\u00eda de Equidad. Published May 2023. Accessed January 11, 2023. https:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-06\/coberturas-de-salud-en-argentina-2022-deiss.pdf."},{"key":"10.1016\/j.puhe.2024.03.027_bib12","unstructured":"Statistics. Census 2022. National Institute of Statistics and Census (INDEC). Published January 31, 2023. Accessed February 9, 2023. https:\/\/www.indec.gob.ar\/indec\/web\/Nivel3-Tema-2-18."},{"key":"10.1016\/j.puhe.2024.03.027_bib13","unstructured":"Global Cancer Observatory. Globocan. International Agency for Research on Cancer. World Health Organization. Accessed February 10, 2023. https:\/\/gco.iarc.fr\/."},{"key":"10.1016\/j.puhe.2024.03.027_bib14","unstructured":"Relative survival by stage at diagnosis (lung cancer). National Cancer Control Indicators. Australian Government. Published April 1, 2019. Accessed February 10, 2023. https:\/\/ncci.canceraustralia.gov.au\/outcomes\/relative-survival-rate\/relative-survival-stage-diagnosis-lung-cancer."},{"issue":"7","key":"10.1016\/j.puhe.2024.03.027_bib15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jtho.2017.04.011","article-title":"The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer","volume":"12","author":"Chansky","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.puhe.2024.03.027_bib16","unstructured":"Life table by country. Expectation of life at age x. World Health Organization (WHO). Published December 6, 2020. Accessed February 14, 2023. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/gho-ghe-life-tables-by-country."},{"key":"10.1016\/j.puhe.2024.03.027_bib17","series-title":"Disability weights","year":"2019"},{"issue":"1","key":"10.1016\/j.puhe.2024.03.027_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12939-020-01168-6","article-title":"Need and inequality in the use of health care services in a fragmented and decentralized health system: evidence for Argentina","volume":"19","author":"Palacios","year":"2020","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.puhe.2024.03.027_bib19","series-title":"An\u00e1lisis de situaci\u00f3n de salud: Republica Argentina","author":"de la Naci\u00f3n","year":"2018"},{"key":"10.1016\/j.puhe.2024.03.027_bib20","unstructured":"Central Bank of Argentina. Exchange rate by date. Central Bank of Argentina. Accessed December 2022. https:\/\/www.bcra.gob.ar\/MediosPago\/Tipos_de_Cambio_SML.asp."},{"key":"10.1016\/j.puhe.2024.03.027_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.vhri.2019.08.042","article-title":"HT3 base de costos UNitarios en salud en Argentina: Una fuente de informaci\u00f3n continuamente actualizada para evaluaciones economicas Y analisis de impacto presupuestario en UN sistema de salud fragmentado","volume":"19","author":"Palacios","year":"2019","journal-title":"Value in Health Regional Issues"},{"key":"10.1016\/j.puhe.2024.03.027_bib22","unstructured":"Grupo AlfaBeta. Precio de medicamentos. Alfa Beta. Published 2020. Accessed April 2023. http:\/\/www.alfabeta.net\/precio\/."},{"key":"10.1016\/j.puhe.2024.03.027_bib23","series-title":"Value chain reports: health, pharmacy and medical equipment","author":"Garfinkel","year":"2016"},{"key":"10.1016\/j.puhe.2024.03.027_bib24","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. cancer.gov. Published March 15, 2023. Accessed November 27, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"8","key":"10.1016\/j.puhe.2024.03.027_bib25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.puhe.2024.03.027_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.puhe.2024.03.027_bib27","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.puhe.2024.03.027_bib28","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.puhe.2024.03.027_bib29","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.puhe.2024.03.027_bib30","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.puhe.2024.03.027_bib31","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.puhe.2024.03.027_bib32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.puhe.2024.03.027_bib33","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.puhe.2024.03.027_bib34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.puhe.2024.03.027_bib35","doi-asserted-by":"crossref","DOI":"10.1590\/0102-311xes081822","article-title":"An\u00e1lisis de costo-efectividad de los cuidados paliativos a pacientes oncol\u00f3gicos de fin de vida","volume":"39","author":"Lamfre","year":"2023","journal-title":"Cad Sa\u00fade P\u00fablica"},{"key":"10.1016\/j.puhe.2024.03.027_bib36","unstructured":"Direcci\u00f3n de Estad\u00edsticas e Informaci\u00f3n de la Salud. Argentina.gob.ar. Published December 4, 2020. Accessed July 20, 2023. https:\/\/www.argentina.gob.ar\/salud\/deis."},{"issue":"10258","key":"10.1016\/j.puhe.2024.03.027_bib37","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.puhe.2024.03.027_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10198-010-0236-4","article-title":"Practical issues in handling data input and uncertainty in a budget impact analysis","volume":"12","author":"Nuijten","year":"2011","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.puhe.2024.03.027_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10147-021-02108-2","article-title":"Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050","volume":"27","author":"Sharma","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.puhe.2024.03.027_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.puhe.2024.03.027_bib41","doi-asserted-by":"crossref","first-page":"e1282","DOI":"10.1016\/S2214-109X(20)30311-9","article-title":"The health and economic burden of smoking in 12 Latin American countries and the potential effect of increasing tobacco taxes: an economic modelling study","volume":"8","author":"Pichon-Riviere","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"9","key":"10.1016\/j.puhe.2024.03.027_bib42","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jama.2020.0734","article-title":"US health care spending by payer and health condition, 1996-2016","volume":"323","author":"Dieleman","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.puhe.2024.03.027_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.20892\/j.issn.2095-3941.2016.0030","article-title":"Estimation of lung cancer burden in Australia, the Philippines, and Singapore: an evaluation of disability adjusted life years","volume":"14","author":"Morampudi","year":"2017","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.puhe.2024.03.027_bib44","unstructured":"Global Burden of Disease (GBD) Compare tables. Argentina. Institute for Health Metrics and Evaluation (IHME). Published 2019. Accessed September 12, 2023. https:\/\/vizhub.healthdata.org\/gbd-compare\/."},{"issue":"9","key":"10.1016\/j.puhe.2024.03.027_bib45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/00019053-200321090-00005","article-title":"Direct treatment costs for patients with lung cancer from first recurrence to death in France","volume":"21","author":"Brand","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.puhe.2024.03.027_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00115677-200614010-00007","article-title":"The cost of lung cancer management in France from the payor's perspective","volume":"14","author":"Vergnen\u00e8gre","year":"2006","journal-title":"Dis Manag Health Outcome"},{"issue":"11","key":"10.1016\/j.puhe.2024.03.027_bib47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1579-2129(06)60589-2","article-title":"Lung cancer diagnosis: hospitalization costs","volume":"42","author":"Arca","year":"2006","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"10.1016\/j.puhe.2024.03.027_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10198-007-0047-4","article-title":"Factors influencing hospital costs of lung cancer patients in Northern Ireland","volume":"9","author":"Fleming","year":"2008","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.puhe.2024.03.027_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13561-021-00322-2","article-title":"Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective","volume":"11","author":"Cicin","year":"2021","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.puhe.2024.03.027_bib50","article-title":"Global burden of lung cancer: implications from current evidence","volume":"5","author":"Zhang","year":"2021","journal-title":"Ann Canc Epidemiol"},{"key":"10.1016\/j.puhe.2024.03.027_bib51","unstructured":"World Health Organization. Lung cancer. World Health Organization. Published June 26, 2023. Accessed August 4, 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer."}],"container-title":["Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350624001434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350624001434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T08:18:57Z","timestamp":1716020337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033350624001434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":51,"alternative-id":["S0033350624001434"],"URL":"https:\/\/doi.org\/10.1016\/j.puhe.2024.03.027","relation":{},"ISSN":["0033-3506"],"issn-type":[{"value":"0033-3506","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung cancer in Argentina: a modelling study of disease and economic burden","name":"articletitle","label":"Article Title"},{"value":"Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.puhe.2024.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of The Royal Society for Public Health.","name":"copyright","label":"Copyright"}]}}